MarketOpen Trading Titan Podcast | Argenica Therapeutics Limited (ASX: AGN) Episode: ARG-007 Shows Significant Neuroprotection in Preclinical Concussion Study Announcement Date: 16 July 2026 Argenica Therapeutics Limited has released positive preclinical data for its lead drug candidate, ARG-007 (xaranetide), from a repeated mild traumatic brain injury, or concussion, study conducted in collaboration with Curtin University and the Perron Institute for Neurological and Translational Science. The study found that a single intravenous dose of one milligram per kilogram, administered thirty minutes after injury, reduced multiple markers of secondary brain injury in a rodent model. According to the company, biomarkers including GFAP, Iba1, MnSOD and NF-L were reduced, with several returning to levels comparable with non-injured control animals. The r ...